Cargando…
The Waveform Fluctuation and the Clinical Factors of the Initial and Sustained Erythropoietic Response to Continuous Erythropoietin Receptor Activator in Hemodialysis Patients
Objectives. Erythropoiesis-stimulating agents (ESA) are the main treatment for anemia in hemodialysis (HD) patients. We evaluated factors determining the response after treatment of a new ESA (continuous erythropoietin erythropoietin receptor activator (CERA)). Methods. 61 HD patients were classifie...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Scientific World Journal
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3349104/ https://www.ncbi.nlm.nih.gov/pubmed/22619601 http://dx.doi.org/10.1100/2012/157437 |
_version_ | 1782232465437360128 |
---|---|
author | Liu, Wen-Sheng Wu, Yueh-Lin Li, Szu-Yuan Yang, Wu-Chang Chen, Tzen-Wen Lin, Chih-Ching |
author_facet | Liu, Wen-Sheng Wu, Yueh-Lin Li, Szu-Yuan Yang, Wu-Chang Chen, Tzen-Wen Lin, Chih-Ching |
author_sort | Liu, Wen-Sheng |
collection | PubMed |
description | Objectives. Erythropoiesis-stimulating agents (ESA) are the main treatment for anemia in hemodialysis (HD) patients. We evaluated factors determining the response after treatment of a new ESA (continuous erythropoietin erythropoietin receptor activator (CERA)). Methods. 61 HD patients were classified by their response at two different timings. First, patients whose hematocrit (Hct) increased 1.5% in the first week were defined as initial responders (IR, n = 16). We compared several parameters between IR and the rest of the study subjects (non-IR, n = 45). Second, patients whose Hct increased 2% in the 4th week were defined as sustained responders (SR, n = 12), and we did a similar comparison. Results. The Hct showed a waveform fluctuation. Compared with the rest, IR had significantly lower platelet counts and higher levels of ferritin, total protein, total bilirubin, and serum sodium, while SR had significantly lower levels of C-reactive protein and low-density lipoprotein (All P < 0.05). In comparison with the rest, higher Hct persisted for 10 weeks in SR but only for two separate weeks (the 1st and 7th week) in IR. Conclusions. The initial and sustained erythropoietic responses are independent from each other and are associated with different factors. Treatment focusing on these factors may improve the response. |
format | Online Article Text |
id | pubmed-3349104 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2012 |
publisher | The Scientific World Journal |
record_format | MEDLINE/PubMed |
spelling | pubmed-33491042012-05-22 The Waveform Fluctuation and the Clinical Factors of the Initial and Sustained Erythropoietic Response to Continuous Erythropoietin Receptor Activator in Hemodialysis Patients Liu, Wen-Sheng Wu, Yueh-Lin Li, Szu-Yuan Yang, Wu-Chang Chen, Tzen-Wen Lin, Chih-Ching ScientificWorldJournal Clinical Study Objectives. Erythropoiesis-stimulating agents (ESA) are the main treatment for anemia in hemodialysis (HD) patients. We evaluated factors determining the response after treatment of a new ESA (continuous erythropoietin erythropoietin receptor activator (CERA)). Methods. 61 HD patients were classified by their response at two different timings. First, patients whose hematocrit (Hct) increased 1.5% in the first week were defined as initial responders (IR, n = 16). We compared several parameters between IR and the rest of the study subjects (non-IR, n = 45). Second, patients whose Hct increased 2% in the 4th week were defined as sustained responders (SR, n = 12), and we did a similar comparison. Results. The Hct showed a waveform fluctuation. Compared with the rest, IR had significantly lower platelet counts and higher levels of ferritin, total protein, total bilirubin, and serum sodium, while SR had significantly lower levels of C-reactive protein and low-density lipoprotein (All P < 0.05). In comparison with the rest, higher Hct persisted for 10 weeks in SR but only for two separate weeks (the 1st and 7th week) in IR. Conclusions. The initial and sustained erythropoietic responses are independent from each other and are associated with different factors. Treatment focusing on these factors may improve the response. The Scientific World Journal 2012-04-19 /pmc/articles/PMC3349104/ /pubmed/22619601 http://dx.doi.org/10.1100/2012/157437 Text en Copyright © 2012 Wen-Sheng Liu et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Clinical Study Liu, Wen-Sheng Wu, Yueh-Lin Li, Szu-Yuan Yang, Wu-Chang Chen, Tzen-Wen Lin, Chih-Ching The Waveform Fluctuation and the Clinical Factors of the Initial and Sustained Erythropoietic Response to Continuous Erythropoietin Receptor Activator in Hemodialysis Patients |
title | The Waveform Fluctuation and the Clinical Factors of the Initial and Sustained Erythropoietic Response to Continuous Erythropoietin Receptor Activator in Hemodialysis Patients |
title_full | The Waveform Fluctuation and the Clinical Factors of the Initial and Sustained Erythropoietic Response to Continuous Erythropoietin Receptor Activator in Hemodialysis Patients |
title_fullStr | The Waveform Fluctuation and the Clinical Factors of the Initial and Sustained Erythropoietic Response to Continuous Erythropoietin Receptor Activator in Hemodialysis Patients |
title_full_unstemmed | The Waveform Fluctuation and the Clinical Factors of the Initial and Sustained Erythropoietic Response to Continuous Erythropoietin Receptor Activator in Hemodialysis Patients |
title_short | The Waveform Fluctuation and the Clinical Factors of the Initial and Sustained Erythropoietic Response to Continuous Erythropoietin Receptor Activator in Hemodialysis Patients |
title_sort | waveform fluctuation and the clinical factors of the initial and sustained erythropoietic response to continuous erythropoietin receptor activator in hemodialysis patients |
topic | Clinical Study |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3349104/ https://www.ncbi.nlm.nih.gov/pubmed/22619601 http://dx.doi.org/10.1100/2012/157437 |
work_keys_str_mv | AT liuwensheng thewaveformfluctuationandtheclinicalfactorsoftheinitialandsustainederythropoieticresponsetocontinuouserythropoietinreceptoractivatorinhemodialysispatients AT wuyuehlin thewaveformfluctuationandtheclinicalfactorsoftheinitialandsustainederythropoieticresponsetocontinuouserythropoietinreceptoractivatorinhemodialysispatients AT liszuyuan thewaveformfluctuationandtheclinicalfactorsoftheinitialandsustainederythropoieticresponsetocontinuouserythropoietinreceptoractivatorinhemodialysispatients AT yangwuchang thewaveformfluctuationandtheclinicalfactorsoftheinitialandsustainederythropoieticresponsetocontinuouserythropoietinreceptoractivatorinhemodialysispatients AT chentzenwen thewaveformfluctuationandtheclinicalfactorsoftheinitialandsustainederythropoieticresponsetocontinuouserythropoietinreceptoractivatorinhemodialysispatients AT linchihching thewaveformfluctuationandtheclinicalfactorsoftheinitialandsustainederythropoieticresponsetocontinuouserythropoietinreceptoractivatorinhemodialysispatients AT liuwensheng waveformfluctuationandtheclinicalfactorsoftheinitialandsustainederythropoieticresponsetocontinuouserythropoietinreceptoractivatorinhemodialysispatients AT wuyuehlin waveformfluctuationandtheclinicalfactorsoftheinitialandsustainederythropoieticresponsetocontinuouserythropoietinreceptoractivatorinhemodialysispatients AT liszuyuan waveformfluctuationandtheclinicalfactorsoftheinitialandsustainederythropoieticresponsetocontinuouserythropoietinreceptoractivatorinhemodialysispatients AT yangwuchang waveformfluctuationandtheclinicalfactorsoftheinitialandsustainederythropoieticresponsetocontinuouserythropoietinreceptoractivatorinhemodialysispatients AT chentzenwen waveformfluctuationandtheclinicalfactorsoftheinitialandsustainederythropoieticresponsetocontinuouserythropoietinreceptoractivatorinhemodialysispatients AT linchihching waveformfluctuationandtheclinicalfactorsoftheinitialandsustainederythropoieticresponsetocontinuouserythropoietinreceptoractivatorinhemodialysispatients |